Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomised, controlled, open-label, non-inferiority trial

Further Publications Dermatology

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Lancet

Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd, Zoliflodacin Phase 3 Study Group

doi: 10.1016/S0140-6736(25)01953-1

Immunodeficiency

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Lancet

Orkin C, Mngqibisa R, Velez JD, Kumar P, Braun DL, Carr A, Bloch M, Walmsley S, Tebas P, Yokomaku Y, Diamond TL, Jackson B, Eves K, Grandhi A, Fuszard M, Klopfer SO, Stamm LM, Fox MC, Kim J

doi: 10.1016/S0140-6736(25)01945-2

Rheumatoid Arthritis

Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with rheumatoid arthritis: a randomised controlled trial

Rheumatology (Oxford)

Esbensen BA, Thomsen T, Roelsgaard IK, Østergaard M, Hetland ML, Andersen L, Tønnesen H, Semb AG, Christensen R

doi: 10.1093/rheumatology/keaf448

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Rheumatoid Arthritis

Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomised clinical trial

Rheumatology (Oxford)

Fadaei S, van der Leeuw MS, Linn-Rasker SP, de Klerk B, Peeters JJW, den Uyl D, Maas-de Kok A, Bos R, Tekstra J, Nap F, Marijnissen ACA, Welsing PMJ, van Laar JM

doi: 10.1093/rheumatology/keaf591

Further Publications Dermatology

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

Lancet

Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, Eid E, McIntyre JK, Bailey I, Furukawa LK, Gorell ES, Harris N, Khosla RK, Peter Lorenz H, Lu Y, Nazaroff J, Grachev ID, Moore AJ

doi: 10.1016/S0140-6736(25)00778-0

Rheumatoid Arthritis

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

BMJ Open

Rayner F, Hiu S, Melville A, Bigirumurame T, Anderson A, Dyke B, Kerrigan S, McGucken A, Prichard J, Shahrokhabadi MS, Hilkens CMU, Buckley CD, McInnes IB, Ng WF, Goodyear C, Teare D, Filer A, Siebert S, Raza K, Pratt A, Baker KF, Isaacs J

doi: 10.1136/bmjopen-2024-092478

Autoimmune Disease

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Ann Rheum Dis

Chevet B, Devauchelle-Pensec V, Pontarini E, Baloche V, Bombardieri M, Bowman SJ, Barnes M, Sreih AG, Liu J, Kelly S, Christodoulou A, Moingeon P, Laigle L, Soret P, Le Dantec C, Pers JO, Alarcon-Riquelme ME, Barturen G, Mariette X, van Roon J, Seror R, Nocturne G, Cornec D, Foulquier N, PRECISEADS Clinical Consortium, NECESSITY consortium

doi: 10.1016/j.ard.2025.11.017

Further Publications Dermatology

Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial

Lancet

Palmbergen WAC, Beekman R, Heeren AM, van Nuenen BFL, Alleman TWH, Verstraete E, Jellema K, Verhagen WIM, Visser LH, de Ruiter GCW, van de Beek D, de Borgie CAJM, Bogaards JA, de Bie RMA, Verhamme C, Dutch CTS study group

doi: 10.1016/S0140-6736(25)00368-X

Related content

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with rheumatoid arthritis: a randomised controlled trial

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomised clinical trial

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial